These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2019-002743-26 Pembrolizumab alone versus pembrolizumab-chemotherapy in first line NSCLC not-yet-due